Progress in health policies on CBD in Argentina and MERCOSUR

Vitor Nifoci and Cristian Emanuel Cabrera

South Health and Policy, 2024, vol. 3, 139-139

Abstract: Cannabidiol (CBD), a compound derived from cannabis, was considered a promising therapeutic option for treating refractory epilepsy. It was shown that, when combined with conventional treatments, it significantly reduced seizures in syndromes such as Dravet, Lennox-Gastaut and Tuberous Sclerosis. In Argentina, its benefits were recognised and public policies were implemented to facilitate access, with the authorisation of the ANMAT and programmes of the Ministry of Health. At a regional level, MERCOSUR promoted joint strategies to improve access to high-cost medicines. However, serious adverse effects were observed, making strict medical supervision necessary. In general, CBD represented a relevant therapeutic alternative, although the need for further research into its safety and efficacy was emphasised.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:southh:2024v3a92

DOI: 10.56294/shp2024139

Access Statistics for this article

More articles in South Health and Policy from AG Editor (Argentina)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().